COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Transplanting Hepatitis C Lungs Into Negative Lung Recipients (SHELTER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03724149
Recruitment Status : Active, not recruiting
First Posted : October 30, 2018
Last Update Posted : March 25, 2020
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
University of Pennsylvania

Brief Summary:
This study is being conducted to determine safety and effectiveness of transplanting lungs from Hepatitis C-positive donors into Hepatitis C-negative patients on the lung transplant waitlist, who will then be treated with appropriate direct-acting antiviral (DAA) after transplantation.

Condition or disease Intervention/treatment Phase
Lung Diseases Drug: Zepatier Drug: Epclusa Phase 1 Phase 2

Detailed Description:
Open-labelled pilot clinical trial of Zepatier (Grazoprevir + Elbasvir), Epclusa (Sofosbuvir + Velpatasvir), or another appropriate DAA in at least 10 HCV-negative subjects receiving a lung transplant from a hepatitis C (HCV)-positive donor. Eligible subjects will receive a lung transplant from a deceased-donor, and then will receive treatment after lung transplantation when infection with HCV is confirmed in these lung transplant recipients. Treatment will be complete after 12 weeks for most subjects.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-Labeled Trial Of Direct-acting Antiviral Treatment Of Hepatitis C-Negative Patients Who Receive Lung Transplants From Hepatitis C-Positive Donors
Actual Study Start Date : December 12, 2018
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : December 31, 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Direct-acting antiviral treatment for HCV Drug: Zepatier
Zepatier (grazoprevir 100mg and elbasvir 50 mg once daily) is taken by mouth for 12 weeks unless a genetic variation is detected. In this case treatment with Zepatier will be extended to 16 weeks. Study subjects with treatment failure will be provided open-label Zepatier + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.

Drug: Epclusa
Epclusa (sofosbuvir 400mg and velpatasvir 100mg once daily) is taken by mouth for 12 weeks. Study subjects with treatment failure will be provided an alternative DAA + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.

Primary Outcome Measures :
  1. Post-treatment Sustained Virologic Response (SVR) [ Time Frame: Baseline to 24 weeks ]
    The primary analysis will be based on a calculation of SVR rates (number of subjects with SVR; negative HCV RNA after completing therapy) / (number of subjects treated post-heart transplantation)

  2. Major Adverse Events Attributable to HCV Therapy in Post-heart Transplant Patients Post-heart Transplant Patients [ Time Frame: Baseline to 52 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 67 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Subject Selection Criteria

Inclusion Criteria:

  • 18-67 years of age
  • Obtained agreement for participation from the lung transplant team
  • No evident contraindication to lung transplantation other than the underlying lung disorder
  • Able to travel to the University of Pennsylvania for routine post-transplant visits and study visits for a minimum of 12 months after transplantation
  • No active illicit substance abuse
  • Women must agree to use birth control in accordance with Mycophenolate Risk Evaluation and Mitigation Strategy (REMS) following transplant due to the increased risk of birth defects and/or miscarriage
  • Both men and women must agree to use at least one barrier method of birth control or remain abstinent following transplant due to risk of HCV transmission
  • Inclusion criteria for treatment (not for entry as study patient) will include any detectable HCV RNA by week 4 post-lung transplantation
  • Able to provide informed consent

Exclusion Criteria:

  • Hepatocellular carcinoma
  • HIV positive
  • HCV RNA positive
  • Hepatitis B surface antigen and/or DNA positive
  • Any chronic liver disease (excluding non-alcoholic fatty liver disease (NAFLD)) that is occurring in the setting of persistently elevated liver enzymes (patients with Alpha-1-antitrypsin lung disease without hepatic involvement are eligible)
  • Significant fibrosis (≥F2 on the Fibroscan)—for patients with cystic fibrosis, the cutoff will be 11kPa (cutoff for F2 for patients with chronic cholestatic liver disease), whereas for all other patients the cutoff will be 8kPa (the cutoff for fatty liver disease used in the THINKER study).
  • Pregnant or nursing (lactating) women
  • Known allergy or intolerance to tacrolimus that would require post-transplant administration of cyclosporine, rather than tacrolimus given the drug-drug interaction between cyclosporine and Zepatier/Epclusa
  • Pre-transplant treatment with amiodarone given the drug-drug interaction between amiodarone and Epclusa
  • Waitlisted for a multi-organ transplant
  • Patients with underlying liver disease with or without liver cirrhosis
  • Patients with cystic fibrosis who have underlying liver disease
  • Re-transplant candidate
  • Use of ECMO or mechanical ventilation as a bridge to lung transplantation
  • Inability to provide study consent
  • Chronic kidney disease with GFR<50 ml/min/1.73 m^2

Relative contraindications for study subjects that will be reviewed on a case-by-case basis by the Lung Transplant Selection Committee and the Principal Investigators:

  • Evidence of end organ damage due to diabetes (e.g. retinopathy, nephropathy, ulcerations) and /or brittle diabetes mellitus (e.g. history of diabetic ketoacidosis) and/or uncontrolled diabetes as evidence by a HgbA1C of 7.5-8.5.
  • Hematologic: Significant coagulation abnormalities, and/or bleeding diatheses.
  • Active or recent solid or liquid malignancy in the past 5 years (apart from select skin malignancies).
  • Patient refusal to receive blood products or transfusions during lung transplant surgery.
  • Psychosocial: Profound neurocognitive impairment with absence of social support.
  • Active mental illness or psychosocial instability
  • Inadequate insurance and/or financial support for post-transplant care.
  • Evidence of drug, tobacco or alcohol abuse within the past six months and failure to satisfy recommended therapy/services/parameters as indicated by social work staff and/or consult team.
  • History of chronic non-adherence to medical recommendations and/or medications
  • PRA >10%.
  • Severe malnutrition, BMI <18
  • Major chronic disabling comorbidity (e.g. lupus, severe arthritis, neurologic diseases, previous stroke with profound residual).
  • Symptomatic or severe vascular disease (History of CABG, Aorta-femoral surgery)

Donor Organ Selection Criteria

Broad goal: To include donors with confirmed HCV expected to have acceptable post-transplant graft outcomes based on large retrospective lung transplant studies.

Inclusion criteria for donors:

  • Detectable HCV RNA
  • Age ≤55 years
  • PaO2/FiO2 ≥300 on FiO2 = 100% and PEEP=5
  • Cigarette use history ≤20 pack years
  • No evidence of cirrhosis
  • No prior treatment of HCV with a DAA-based therapy
  • Can be isolated hepatitis B Core IgG positive, but cannot have a detectable HBV Core IgM, HBSAg, and/or HBV DNA (positive HBV NAT test)

Donor Exclusion Criteria:

  • Donation after circulatory death determination (DCDD)
  • HIV positive

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03724149

Layout table for location information
United States, Pennsylvania
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
University of Pennsylvania
Merck Sharp & Dohme Corp.
Layout table for investigator information
Study Director: Peter Reese, MD, MSCE Perelman School of Medicine at the University of Pennsylvania

Layout table for additonal information
Responsible Party: University of Pennsylvania Identifier: NCT03724149    
Other Study ID Numbers: 829397
First Posted: October 30, 2018    Key Record Dates
Last Update Posted: March 25, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by University of Pennsylvania:
Lung Disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis C
Lung Diseases
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Flaviviridae Infections
RNA Virus Infections
Respiratory Tract Diseases
Sofosbuvir-velpatasvir drug combination
Elbasvir-grazoprevir drug combination
Antiviral Agents
Anti-Infective Agents